capecitabine has been researched along with Chemotherapy-Induced Acral Erythema in 137 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 99 (72.26) | 24.3611 |
| 2020's | 38 (27.74) | 2.80 |
| Authors | Studies |
|---|---|
| Cherem-Kibrit, M; Colmenero-Mercado, JO; Deneken-Hernandez, Z; Gutiérrez-Andrade, L; Rodríguez-Gutiérrez, G | 1 |
| He, L; He, X; Hu, H; Liu, J; Lou, Y; Qiu, Y; Wang, J; Wang, Q; Yang, X; Yu, L; Zeng, S | 1 |
| Elyasi, S; Hosseini, S; Rasta, S; Taghizadeh-Kermani, A | 1 |
| Kwakman, JJM; Mol, L; Punt, CJA | 1 |
| Chang, H; Chen, R; Cheng, J; Hu, T; Peng, X; Wang, J; Wang, Q; Xie, Y | 1 |
| Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C | 1 |
| Ikemura, K; Okuda, M; Shimazu, K; Shintani, T; Takemura, M; Toyozumi, Y; Ueda, M; Yoshinami, T | 1 |
| Batra, A; Cheung, WY; Gogia, A; Gupta, I; Gupta, N; Kumar, A; Pandey, RM; Pramanik, R; Prasad, CP; Santhosh, A; Sharma, A | 1 |
| Franco, PIG; Li, RK; Pandy, JGP | 1 |
| Krishna Sasanka, KSBS; Thangaraju, P; Uppala, PK; Varghese, AM; Velmurugan, H; Yella, SST | 1 |
| Ahiko, Y; Aikou, S; Boku, N; Furukawa, N; Iimura, Y; Ishibashi, M; Kuroda, S; Nojima, M; Shida, D; Tanabe, T | 1 |
| Hung, CH; Kao, YS; Lo, CH; Tu, YK | 1 |
| Barton, DL; Chittiprolu, A; Cho, Y; Gong, Y; Harden, K; Harris, MR; Jiang, Y; Mason, M; Zhang, X | 1 |
| Chen, Y; Hu, J; Luo, S; Lv, D; Wu, Z; Xie, X; Yang, B; Zhang, S | 1 |
| Bins, S; de With, M; El Bouazzaoui, S; Homs, MYV; Maasland, DC; Mathijssen, RHJ; Mostert, B; Mulder, TAM; Oomen-de Hoop, E; van Doorn, L; van Schaik, RHN | 1 |
| Abdin, AA; Hedya, SE; Kotb, HM; Mashaly, ME | 1 |
| André, T; Bodoky, G; Cremolini, C; Heinemann, V; Maughan, T; McDermott, R; Osterlund, P; Pfeiffer, P; Punt, CJA; Teske, AJ; Van Cutsem, E | 1 |
| Ishikawa, T; Kanbayashi, Y; Otsuji, E; Taguchi, T; Takayama, K | 1 |
| Fan, Y; He, M; Lan, B; Li, Q; Liu, J; Luo, Y; Ma, F; Mo, H; Wang, J; Wang, Z; Xu, B; Yuan, P; Zhang, P | 1 |
| Barreda-Hernández, D; Fernández-Carballido, AM; Sánchez-Gundín, J; Torres-Suárez, AI | 1 |
| Ban, L; Cui, X; Wang, D; Zhang, B; Zhang, X; Zhao, J | 1 |
| Chen, SC; Hsu, YH; Lin, YF; Shen, WC; Wang, CH | 1 |
| Cai, R; Chen, S; Fan, Y; Guan, X; Li, Q; Lin, S; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Yue, J; Zhang, P | 1 |
| Alsarheed, A; Cobos, GA; LaChance, A; Laga, AC; LeBoeuf, N; Nelson, CA; Vleugels, RA | 1 |
| Ariyoshi, K; Hamaguchi, R; Iwase, S; Miura, K; Miyata, G; Ohori, H; Oshio, H; Oyamada, S; Sato, T; Takahashi, K; Tsuchiya, T | 1 |
| Aebi, S; Amstutz, U; Froehlich, TK; García-González, X; Hamzic, S; Joerger, M; Kummer, D; Largiadèr, CR; López-Fernández, LA; Meulendijks, D; Palles, C; Schellens, JHM; Thomlinson, I | 1 |
| Abdelhamid, T; El Desouky, ED; Khaled, H; Nassar, H; Omran, MA; Rashad, N; Shouman, SA | 1 |
| He, S; Huang, C; Huang, L; Li, Q; Liao, X; Yu, Q; Yuan, X | 1 |
| Endo, I; Fujii, S; Ichikawa, Y; Ishibe, A; Oba, MS; Ota, M; Watanabe, J; Watanabe, K | 1 |
| Chavan, N; Desouza, A; Gupta, S; Gupta, T; Kapoor, A; Mandavkar, S; Mirani, J; Murugan, K; Nashikkar, C; Ostwal, V; Ramaswamy, A; Saklani, A | 1 |
| Alba, E; Benítez, J; Caronia, D; Cuadrado, A; de la Torre-Montero, JC; García-Saenz, JA; González-Neira, A; Kojic, A; López-Fernández, LA; Losada, A; Lozano, M; Martín, M; Milne, RL; Moreno, LT; Nuñez-Torres, R; Pérez-Moreno, M; Pita, G; Ribelles, N; Ruiz-Pinto, S; Shahbazi, MN | 1 |
| Jaehde, U; Ko, YD; Krolop, L; Ringsdorf, S; Schmulenson, E; Simons, S | 1 |
| Abdi, A; Alsaloumi, L; Basgut, B; Shawagfeh, S | 1 |
| Lian, S; Zhang, X; Zhang, Y; Zhao, Q | 1 |
| Astras, G; Charalambous, A; Filippou, E; Paikousis, L; Tsitsi, T | 1 |
| Cao, LJ; Dong, SQ; He, YQ; Huang, JW; Jia, WH; Li, XZ; Wang, TM; Wu, ZY; Xue, WQ; Yang, DW; Zhang, JB; Zhang, PF; Zheng, XH | 1 |
| An, X; Bi, XW; Cai, L; Cao, Y; Chen, QJ; Guo, Y; He, ZY; Hong, RX; Hua, X; Huang, H; Huang, JJ; Huang, ZZ; Jiang, KK; Ke, YL; Li, JB; Lin, HX; Lin, Y; Liu, XM; Pang, DM; Peng, RJ; Shi, W; Shi, YX; Song, CG; Su, YH; Tang, J; Wang, SS; Wang, X; Wang, XM; Wang, XY; Xia, W; Xu, F; Xue, C; Yuan, ZY; Zeng, J; Zhang, AQ; Zhang, LH; Zhao, L; Zhong, YY | 1 |
| Beijnen, JH; Derissen, EJB; Dorlo, TPC; Huitema, ADR; Jacobs, BAW; Janssen, JM; Marchetti, S; Roosendaal, J | 1 |
| Astras, G; Charalambous, A; Paikousis, L; Stavrinou, M; Tsitsi, T | 1 |
| Chen, R; Chen, S; Chen, X; Hong, C; Huang, Z; Ke, C; Lei, J; Liu, H; Lu, W; Lv, H; Su, R; Sun, Z; Tan, X; Wei, Y; Yang, P | 1 |
| Hiromoto, S; Inoue, M; Kawashiri, T; Kobayashi, D; Mine, K; Shimazoe, T; Uchida, M; Yamanaka, N | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Gianni, L; Green, M; Hoersch, S; Krop, IE; Miles, D; Pegram, M; Verma, S; Welslau, M; Xu, J | 1 |
| De Sanctis, V; Minniti, G; Nicosia, L; Osti, MF; Russo, I; Valeriani, M | 1 |
| Aogi, K; Im, SA; Im, YH; Iwata, H; Jeong, J; Kim, A; Kim, SB; Kuroi, K; Lee, ES; Lee, SJ; Masuda, N; Ohashi, Y; Ohno, S; Ohtani, S; Park, BW; Park, KH; Sasano, H; Takao, S; Toi, M; Yanagita, Y; Yokota, I | 1 |
| Allahyari, A; Elyasi, S; Karimi, G; Shojaee, FSR | 1 |
| Chay, WY; Chia, JWK; Choo, SP; Dent, RA; Koh, KX; Koo, WH; Kwok, LL; Lo, SK; Loh, M; Mok, ZY; Ng, RCH; Soong, RCT; Syn, N; Tan, S; Tham, CK; Toh, HC; Wong, NS; Yap, YS | 1 |
| Baselga, J; Bergh, J; Bermejo, B; Chan, A; Costa, F; Gómez, HL; Gómez, P; Gradishar, WJ; Huang, L; Hudis, CA; Maeda, P; Mángel, L; Meinhardt, G; Melichar, B; Nagai, SE; Rapoport, BL; Roché, H; Schwartzberg, LS; Zamagni, C; Zhang, J | 1 |
| Anders, CK; Chao, YL | 1 |
| Cubero, D; de Melo Sette, CV; Del Giglio, A; Fonseca, F; Martins, JC; Mutti, H; Scontre, VA | 1 |
| Chen, WJ; Chen, Y; Huang, XZ; Wang, ZN; Wu, CC; Wu, J; Zhang, X | 1 |
| Aapro, M; Bondarenko, I; Campone, M; Krishnamurthy, S; Lebedeva, L; Martin, M; Roman, L; Sakaeva, D; Vedovato, JC | 1 |
| Creemers, A; de Waal, L; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH | 1 |
| Akiyoshi, T; Fujimoto, Y; Fukunaga, Y; Kawakami, K; Konishi, T; Matsusaka, S; Nagayama, S; Shinozaki, E; Suenaga, M; Sugisaki, T; Ueno, M; Yamaguchi, T; Yokokawa, T | 1 |
| Ayala, F; Cristaudo, A; Fabbrocini, G; Ionescu, MA; Panariello, L; Pellicano, M; Robert, G | 1 |
| Hattori, M; Hayashi, T; Iwata, H; Kobayashi, N; Nakada, T; Saito, K; Sawaki, M; Toyama, T; Tsuneizumi, M; Yokota, I; Yoshimura, A | 1 |
| Fuss, H; Jung, S; Lademann, J | 1 |
| Jiang, W; Lou, Y; Qiu, Y; Wang, Q; Wang, X; Zeng, S; Zhao, Q; Zheng, J; Zheng, Y | 1 |
| Brinch, CM; Ekblad, L; Hermann, KL; Holm, VH; Jensen, BK; Jensen, BV; Larsen, FO; Lindgaard, SC; Michelsen, H; Nelausen, KM; Nielsen, DL; Nørgaard, HH; Soerensen, PG; Theile, S | 1 |
| Creemers, GM; Hendriks, MP; Koopman, M; Kwakman, JJM; Los, M; Mol, L; Muller, EW; Polée, MB; Punt, CJA; Simkens, LHJ; Tije, AJT; van Alphen, RJ; van de Wouw, YAJ; van der Velden, AMT; van Rooijen, JM; van Voorthuizen, T; van Werkhoven, E | 1 |
| Amini, A; Amouzegar, A; Azadeh, P; Farasatinasab, M; Ghiasi, HA; Mokhtari, M; Yaghobi Joybari, A; Yaseri, M | 1 |
| Diaz, CL; Hwang, J; Johns, C; Kerridge, WD; Ko, AH; Tempero, MA | 1 |
| Lu, Y; Sun, Y; Wang, Z; Zheng, S; Zhou, Y | 1 |
| Chau, I; Cunningham, D; Hubner, RA; Worsnop, F | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R | 1 |
| Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K | 1 |
| Seaman, SR; Wason, JM | 1 |
| Fuyuki, A; Hata, Y; Kanoshima, K; Kuriyama, H; Kuwabara, H; Matsuura, T; Murata, Y; Taniguchi, R; Tomeno, W; Uchiyama, T | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Ilyas, S; Saif, MW; Wasif, K | 1 |
| Braun, JJ; de Graaf, H; de Groot, SM; de Jongh, FE; Hamaker, ME; Los, M; Maartense, E; Nortier, JW; Schrama, JG; Seynaeve, C; Smorenburg, CH; van Leeuwen-Stok, AE; van Tinteren, H; Wymenga, AN | 1 |
| Fujii, C; Fujino, M; Fukunaga, M; Hachino, Y; Hamaguchi, Y; Imamura, H; Iseki, C; Ishizaka, T; Kamigaki, S; Kawabata, R; Kawase, T; Kimura, Y; Yamamoto, E | 1 |
| Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE | 1 |
| Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K | 1 |
| Chen, J; Chen, X; Dai, C; Wu, X; Yu, B; Zhao, C; Zhou, C | 1 |
| Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI | 1 |
| Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K | 1 |
| Arrowood, CA; Honeycutt, W; Howard, L; Hurwitz, HI; Latta, K; Meadows, KL; Niedzwiecki, D; Rushing, C | 1 |
| Jiang, N; Li, Z; Xu, Y | 1 |
| Fuxius, S; Hahn, LJ; Hurst, U; Lerchenmüller, C; Luhn, B; Müller, V; Soeling, U; Steffens, CC; Vehling-Kaiser, U; Wohlfarth, T; Zaiss, M | 1 |
| Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K | 1 |
| Alonso, R; Caballero, R; Calvo, L; Caronia, D; Carrasco, E; Casado, A; Chacón, JI; Constenla, M; De la Haba, J; De la Torre-Montero, JC; García-Sáenz, JÁ; González-Neira, A; Guerra, E; Heras, L; Hernando, B; Jimeno, MÁ; Lluch, A; Martín, M; Martínez, N; Muñoz, M; Pita, G; Ramos, M; Ruíz-Borrego, M; Zamora, P | 1 |
| Ishii, K; Kanamoto, A; Miyanaga, S; Noto, M; Takeda, T; Tani, T; Yagi, M | 1 |
| Chavarri-Guerra, Y; Soto-Perez-de-Celis, E | 1 |
| Dong, WG; He, AB; Luo, RF; Peng, XL; Song, J; Tang, Y; Zhang, JX | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Greten, TF; Haas, M; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Kruger, S; Laubender, RP; Märten, A; Modest, DP; Stintzing, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Al-Batran, SE; Bolz, G; Gencer, D; Hegewisch-Becker, S; Hofheinz, RD; Kronawitter, U; Loeffler, LM; Potenberg, J; Schneeweiss, A; Schulz, H; Stahl, M; Tauchert, F | 1 |
| Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K | 1 |
| Hama, T; Kawakami, K; Mae, Y; Mizunuma, N; Suenaga, M; Sugita, K; Suzuki, K; Watanabe, H; Yamaguchi, T; Yokokawa, T | 1 |
| Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A | 1 |
| Hayakawa, M; Koketsu, H; Matsuda, S; Nagata, N | 1 |
| Busakhala, N; Chite, F; Kigen, G; Loehrer, P; Njiru, E | 1 |
| Anghel, R; Beslija, S; Brodowicz, T; Inbar, MJ; Kahan, Z; Lang, I; Messinger, D; Stemmer, SM; Vrbanec, D; Zielinski, C | 1 |
| Achrekar, MS; Carvalho, MD; D'souza, A; Govindarajan, S; Gupta, S; Murugan, K; Ostwal, V | 1 |
| Arnold, D; Engelen, A; Göhler, T; Hinke, A; Höffkes, HG; Quidde, J; Schirrmacher-Memmel, S; Schröder, JK; Stein, A; Tschechne, B; Valdix, AR; Wohlfarth, T | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS | 1 |
| Muss, HB; Nishijima, TF; Suzuki, M | 1 |
| Hara, S; Miwa, Y; Naito, M; Shimamoto, C; Yamamoto, T | 1 |
| Binkhorst, L; Bins, S; Mathijssen, R; van Doorn, L; Veelenturf, S | 1 |
| Hong, D; Hu, H; Liu, L; Lou, Y; Wang, Q; Zeng, S; Zheng, J | 1 |
| Chen, J; Chen, M; He, Q; Li, G; Luo, P; Peng, X; Shao, J; Xu, Z; Yang, B; Zhu, H; Zhu, Y | 1 |
| Ljubojevic Hadzavdic, S; Murtezani, I; Skerlev, M; Stulhofer Buzina, D | 1 |
| Hamada, C; Hazama, S; Ike, H; Ishida, H; Ishiguro, M; Kondo, K; Kunieda, K; Maeda, K; Masuko, H; Mishima, H; Morita, T; Nishimura, G; Okajima, M; Sadahiro, S; Saji, S; Sakamoto, J; Sasaki, K; Sugihara, K; Suto, T; Tomita, N | 1 |
| Baars, A; Boot, H; Kwakman, JJM; Pfeiffer, P; Pruijt, JFM; Punt, CJA; Winther, SB | 1 |
| Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N | 1 |
| Chi, HD; Chua, D; Jiang, ZF; Liu, DG; Luo, RC; Martin, AM; Newstat, B; Preston, A; Shao, ZM; Wang, L; Wang, XJ; Xu, BH; Yeo, W; Yu, SY | 1 |
| Girard, P; Paule, I; Tod, M | 1 |
| Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA | 1 |
| Almeida da Cruz, L; Ferrari, CL; Hoff, PM; Riechelmann, RS | 1 |
| Freyer, G; Girard, P; Hénin, E; Paule, I; Tod, M; You, B | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N | 1 |
| Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z | 1 |
| Cassidy, J; Díaz-Rubio, E; Gilberg, F; McKendrick, J; Scheithauer, W; Seitz, JF; Twelves, C; Van Hazel, G; Wong, A | 1 |
| Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX | 1 |
| Baker, SG; Cotliar, JA; Gunawardane, ND; Hoesly, FJ | 1 |
| Brown, JB; Kadoyama, K; Miki, I; Okuno, Y; Sakaeda, T; Tamura, T | 1 |
| Akagi, Y; Ando, K; Emi, Y; Kakeji, Y; Kitazono, M; Maehara, Y; Morita, M; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Sakaguchi, Y; Samura, H; Shirouzu, K; Sirzen, F; Tokunaga, S | 1 |
| Al-Ahwal, MS | 1 |
| Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH | 1 |
| Agharbi, FZ; Benhemmne, H; Daoudi, K; Elmesbahi, O; Mernissi, FZ; Meziane, M; Mikou, O | 1 |
| Fukuda, M; Hanada, K; Hata, H; Ikai, I; Kubo, K; Moriyama, S; Murakami, T; Ogiso, S; Okazaki, S; Okuchi, Y; Otani, T; Sakata, S; Setoguchi, Y; Tanaka, M; Tani, M; Une, Y; Yamaguchi, T; Yamato, T; Yasui, H | 1 |
| Fang, H; Qiao, J | 1 |
| Gibson, B; Matherne, R; Wiesenthal, A | 1 |
| Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N | 1 |
| Azuma, Y; Fujiwara, Y; Hata, K; Hirakawa, A; Makino, Y; Morikawa, N; Ryushima, Y; Sai, K; Saito, Y; Tohkin, M; Udagawa, R; Yamamoto, H; Yokote, N | 1 |
| Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S | 1 |
| Begent, R; Gafson, AR; Goodkin, O | 1 |
| Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G | 1 |
| Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R | 1 |
| Carrié, S; Cottu, P; De Rycke, Y; Falcou, MC; Llambrich, C; Medjbari, M | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Stiefelhagen, P | 1 |
| Burkholder, I; Gencer, D; Heinemann, V; Hochhaus, A; Hofheinz, RD; Laubender, RP; Stintzing, S; von Weikersthal, LF | 1 |
| Barrios, CH; Blum, JL; Feldman, N; Gralow, J; Lee, LF; McKenna, EF; Scotto, N; Verma, S | 1 |
| Chan, AO; Chan, HY; Ng, CM; Shek, CC; Tiu, SC | 1 |
| Amamori, K; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamagiwa, K; Yamanda, T | 1 |
| Furuya, Y; Ishida, T; Masuda, N; Matsunami, N; Miyashita, M; Nagata, T; Nakayama, T; Noguchi, S; Nomura, M; Oba, K; Sakamoto, J; Taguchi, T; Wakita, K; Yamamoto, D; Yoshidome, K; Yoshino, H | 1 |
17 review(s) available for capecitabine and Chemotherapy-Induced Acral Erythema
| Article | Year |
|---|---|
Capecitabine induced fingerprint loss: Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Receptor, ErbB-2 | 2022 |
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Topics: Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Neoplasms; Pyridoxine; Randomized Controlled Trials as Topic; Sorafenib | 2022 |
Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Network Meta-Analysis; Pyridoxine; Randomized Controlled Trials as Topic; Silymarin | 2022 |
Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Dermatoglyphics; Docetaxel; Female; Hand-Foot Syndrome; Humans | 2020 |
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Hand-Foot Syndrome; Humans; Hydro-Lyases; Neoplasms; Thymidylate Synthase | 2020 |
Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Female; Hand-Foot Syndrome; Humans; Middle Aged; Progression-Free Survival; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2020 |
Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
Topics: Antineoplastic Agents; Capecitabine; Hand-Foot Syndrome; Humans; Pyridoxine | 2021 |
Two Cases of Capecitabine-Induced Ileitis in Patients Treated with Radiochemotherapy to the Pelvis and Review of the Literature.
Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Chemoradiotherapy; Colonoscopy; Female; Hand-Foot Syndrome; Humans; Ileitis; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Rectum; Tomography, X-Ray Computed | 2018 |
Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Hand-Foot Syndrome; Humans; Incidence | 2018 |
Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Hand-Foot Syndrome; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Treatment Outcome; Young Adult | 2018 |
Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Drug Combinations; Hand-Foot Syndrome; Humans; Odds Ratio; Oxonic Acid; Risk Factors; Stomach Neoplasms; Survival Analysis; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2015 |
A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Hand-Foot Syndrome; Humans; Random Allocation; Stomatitis; Treatment Outcome | 2016 |
Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Female; Hand-Foot Syndrome; Humans | 2016 |
Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Review Literature as Topic | 2012 |
Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Bacteremia; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Pseudomonas Infections; Superinfection | 2011 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Nausea; Neutropenia; Salvage Therapy; Stomatitis; Survival Analysis; Taxoids; Thrombocytopenia; Vomiting; Young Adult | 2013 |
Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult | 2012 |
52 trial(s) available for capecitabine and Chemotherapy-Induced Acral Erythema
| Article | Year |
|---|---|
Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Curcumin; Female; Hand-Foot Syndrome; Humans; Lawsonia Plant; Ointments | 2022 |
Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Quality of Life | 2022 |
Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Topics: Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Hand-Foot Syndrome; Humans | 2022 |
Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndrome; Humans; Hydrocortisone; Oxaliplatin | 2022 |
Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Diarrhea; Female; Hand-Foot Syndrome; Humans; Nausea; Prospective Studies; Receptor, ErbB-2; Vomiting | 2023 |
Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cystine; Diarrhea; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Glutamates; Hand-Foot Syndrome; Humans; Male; Middle Aged; Stomatitis | 2020 |
Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study.
Topics: Abdominal Pain; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Constipation; Diarrhea; Female; Hand-Foot Syndrome; Humans; Letrozole; Middle Aged; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2020 |
The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Combination; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Negative Results; Pharmaceutical Preparations; Phytotherapy; Plant Extracts; Pyridoxine; Young Adult | 2020 |
Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
Topics: Capecitabine; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Prospective Studies; Quality of Life | 2020 |
A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Topics: Activities of Daily Living; Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Capecitabine; Double-Blind Method; Doxorubicin; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pilot Projects; Polyethylene Glycols; Pyridoxine; Quality of Life; Treatment Outcome; Vitamin B Complex | 2021 |
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinica
Topics: Adult; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Maintenance Chemotherapy; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Observation; Triple Negative Breast Neoplasms | 2021 |
Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Biological Variation, Population; Capecitabine; Computer Simulation; Datasets as Topic; Dose-Response Relationship, Drug; Drug Dosage Calculations; Hand-Foot Syndrome; Humans; Leukocytes, Mononuclear; Markov Chains; Models, Biological; Neoplasms; Primary Cell Culture; Prodrugs; Uridine Triphosphate | 2021 |
A randomised controlled feasibility trial to evaluate Lawsonia inermis (henna)'s effect on palmar-plantar erythrodysesthesia induced by capecitabine or pegylated liposomal doxorubicin.
Topics: Adult; Aged; Capecitabine; Doxorubicin; Drug Interactions; Feasibility Studies; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Naphthoquinones; Polyethylene Glycols; Treatment Outcome | 2021 |
The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Hand-Foot Syndrome; Humans | 2021 |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Lapatinib; Male; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab; Vomiting; Young Adult | 2017 |
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Receptor, ErbB-2; Survival Analysis; Triple Negative Breast Neoplasms | 2017 |
Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Capecitabine; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Phytotherapy; Silybum marianum; Silymarin | 2017 |
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Chi-Square Distribution; Dihydrouracil Dehydrogenase (NADP); Double-Blind Method; Drug Administration Schedule; Female; Folic Acid; Genetic Predisposition to Disease; Genome-Wide Association Study; Hand-Foot Syndrome; Humans; Incidence; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Logistic Models; Male; Membrane Proteins; Microfilament Proteins; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyridoxine; Risk Assessment; Risk Factors; Severity of Illness Index; Singapore; Time Factors; Treatment Outcome | 2017 |
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Receptor, ErbB-2; Sorafenib; Taxoids; Treatment Outcome | 2017 |
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy-Induced Febrile Neutropenia; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Progression-Free Survival; Quality of Life; Survival Analysis; Taxoids; Vinblastine | 2018 |
A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Diarrhea; Feasibility Studies; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2018 |
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyridoxine | 2018 |
Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemoembolization, Therapeutic; Fatigue; Female; Hand-Foot Syndrome; Hepatic Artery; Humans; Liver Neoplasms; Middle Aged; Oxaliplatin; Peripheral Nervous System Diseases; Progression-Free Survival | 2019 |
Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Hand-Foot Syndrome; Humans; Incidence; Kaplan-Meier Estimate; Oxonic Acid; Progression-Free Survival; Tegafur | 2019 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Capecitabine; Cognition Disorders; Comorbidity; Deoxycytidine; Depression; Doxorubicin; Fatigue; Female; Fluorouracil; Frail Elderly; Geriatric Assessment; Hand-Foot Syndrome; Humans; Mental Status Schedule; Palliative Care; Polyethylene Glycols; Polypharmacy; Risk Factors; Stomatitis; Treatment Outcome | 2014 |
Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drugs, Chinese Herbal; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Treatment Outcome; Young Adult | 2014 |
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Pilot Projects; Piperazines; Placebos; Protein Kinase Inhibitors; Purines; Pyrroles; Sildenafil Citrate; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Pharmacogenetics; Treatment Outcome | 2015 |
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Germany; Hand-Foot Syndrome; Humans; Incidence; Keratolytic Agents; Male; Middle Aged; Ointments; Primary Prevention; Quality of Life; Severity of Illness Index; Skin Cream; Surveys and Questionnaires; Time Factors; Treatment Failure; Urea | 2015 |
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Japan; Male; Middle Aged; Pyridoxine; Risk Factors; Time Factors; Treatment Failure; Young Adult | 2014 |
Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Treatment Outcome | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; China; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2016 |
Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Treatment Outcome | 2017 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Exanthema; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Remission Induction | 2011 |
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2012 |
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids; Treatment Outcome | 2012 |
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pharmacokinetics; Pilot Projects; Prognosis; Treatment Outcome; Young Adult | 2012 |
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazoles; Sulfonamides | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Placebos; Pyridoxine | 2012 |
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2012 |
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Rectal Neoplasms; Treatment Outcome | 2012 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Sample Size; Survival Analysis | 2013 |
68 other study(ies) available for capecitabine and Chemotherapy-Induced Acral Erythema
| Article | Year |
|---|---|
P38 MAPK, NF-κB, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression.
Topics: Animals; Capecitabine; Hand-Foot Syndrome; Interleukin-6; Interleukin-8; Mice; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Signal Transduction; STAT3 Transcription Factor | 2022 |
Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.
Topics: Capecitabine; Cardiotoxicity; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndrome; Humans; Prospective Studies; Rectal Neoplasms | 2022 |
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Fluorouracil; Genetic Variation; Genome-Wide Association Study; Hand-Foot Syndrome; Humans; Inflammation; Oxaliplatin; Psoriasis; Sialyltransferases | 2022 |
Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.
Topics: Breast Neoplasms; Capecitabine; Female; Hand-Foot Syndrome; Humans; Proton Pump Inhibitors; Retrospective Studies | 2022 |
Capecitabine and Hand-foot Syndrome: A Case Report.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged | 2023 |
Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Electronic Health Records; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Patient Reported Outcome Measures; Pilot Projects | 2022 |
Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil.
Topics: Animals; Capecitabine; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Mice; Pyroptosis; Quality of Life; Thymidine Phosphorylase | 2023 |
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Hand-Foot Syndrome; Humans; Pharmacogenomic Testing; Prospective Studies; Quality of Life | 2023 |
Thymidine phosphorylase as a molecular target for quercetin-incorporated collagen matrix in the prevention of hand-foot syndrome induced by capecitabine in rats.
Topics: Animals; Antioxidants; Capecitabine; Hand-Foot Syndrome; Quality of Life; Quercetin; Rats; Rats, Sprague-Dawley; Thymidine Phosphorylase | 2023 |
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndrome; Humans; Immunologic Factors; Irinotecan | 2023 |
Risk Factors of Capecitabine-Induced Hand-Foot Syndrome: A Single-Institution, Retrospective Study.
Topics: Capecitabine; Hand-Foot Syndrome; Humans; Quality of Life; Retrospective Studies; Risk Factors | 2023 |
Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Compounding; Drugs, Generic; Female; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Male; Middle Aged; Mucositis; Neutropenia; Oxaliplatin; Peripheral Nervous System Diseases; Retrospective Studies; Thrombocytopenia | 2019 |
Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy.
Topics: Activities of Daily Living; Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cross-Sectional Studies; Docetaxel; Female; Hand-Foot Syndrome; Humans; Middle Aged; Surveys and Questionnaires; Taiwan | 2019 |
Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Female; Genotype; Hand-Foot Syndrome; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Thymidylate Synthase | 2019 |
Capecitabine-Related Eruption Mimicking Dermatomyositis in 2 Patients With Metastatic Breast Cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dermatomyositis; Diagnosis, Differential; Female; Hand-Foot Syndrome; Humans; Middle Aged | 2020 |
SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Capecitabine; Case-Control Studies; China; Colorectal Neoplasms; Cyclooxygenase 2; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Polymorphism, Single Nucleotide; Prostaglandin-E Synthases; Receptors, Prostaglandin E; Risk Factors; Signal Transduction; Stomach Neoplasms; Young Adult | 2020 |
Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cadherins; Capecitabine; Cell Line; Female; Genetic Predisposition to Disease; Hand-Foot Syndrome; Haplotypes; Humans; Keratinocytes; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Risk | 2021 |
Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Male; Markov Chains; Middle Aged; Neoplasms; Patient Reported Outcome Measures; Prognosis; Prospective Studies | 2020 |
Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Hand-Foot Syndrome; Humans; Hydro-Lyases; Male; Middle Aged; Polymorphism, Single Nucleotide; Thymidylate Synthase | 2021 |
Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome.
Topics: Animals; Capecitabine; Disease Models, Animal; Hand-Foot Syndrome; Mice; Mice, Inbred ICR; Omeprazole; Proton Pump Inhibitors | 2021 |
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Mastectomy; Middle Aged; Nausea; Neutropenia; Pharmacogenomic Testing; Polymorphism, Genetic; Prodrugs; Thymidylate Synthase; Vomiting | 2018 |
Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; C-Reactive Protein; Capecitabine; Curcuma; Curcumin; Female; Gastrointestinal Neoplasms; Hand-Foot Syndrome; Humans; Interleukin-6; Male; Middle Aged; Phytotherapy; Pilot Projects; Quality of Life; Serum Albumin; Surveys and Questionnaires; Tumor Necrosis Factor-alpha | 2018 |
Topical non-occlusive polymers in hand-foot syndrome.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Agents; Capecitabine; Docetaxel; Female; Hand-Foot Syndrome; Humans; Italy; Male; Middle Aged; Ointments; Polymers; Prospective Studies; Quality of Life; Severity of Illness Index; Taxoids; Treatment Outcome | 2018 |
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib | 2018 |
Identification of the Novel Capecitabine Metabolites in Capecitabine-Treated Patients with Hand-Foot Syndrome.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Arylamine N-Acetyltransferase; Capecitabine; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Discriminant Analysis; Female; Hand-Foot Syndrome; Humans; Least-Squares Analysis; Magnetic Resonance Spectroscopy; Male; Microsomes, Liver; Middle Aged; Tandem Mass Spectrometry | 2018 |
Capecitabine induced fingerprint changes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Female; Hand-Foot Syndrome; Humans; Iran; Male; Middle Aged | 2019 |
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Cohort Studies; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Outcome and Process Assessment, Health Care; Oxaloacetates; Oxonic Acid; Paraneoplastic Polyneuropathy; Stomach Neoplasms; Tegafur | 2019 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hand-Foot Syndrome; Humans; Lethargy; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Using continuous data on tumour measurements to improve inference in phase II cancer studies.
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II as Topic; Computer Simulation; Data Interpretation, Statistical; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Neoplasms | 2013 |
[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Receptor, ErbB-2; Salvage Therapy; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab | 2013 |
Topical henna ameliorated capecitabine-induced hand-foot syndrome.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Naphthoquinones; Pancreatic Neoplasms | 2014 |
[Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Arginine; Butyrates; Capecitabine; Deoxycytidine; Female; Fluorouracil; Glutamine; Hand-Foot Syndrome; Humans; Hydroxy Acids; Male; Middle Aged; Neoplasms | 2013 |
Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genome-Wide Association Study; Genomics; Hand-Foot Syndrome; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide | 2014 |
[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Stomach Neoplasms | 2013 |
The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Female; Hand-Foot Syndrome; Humans; Lupus Erythematosus, Cutaneous | 2016 |
Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Germany; Hand-Foot Syndrome; Humans; Middle Aged; Product Surveillance, Postmarketing; Quality of Life; Risk Assessment; Surveys and Questionnaires | 2014 |
[A case of lacrimal duct obstruction caused by capecitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorometholone; Fluoroquinolones; Fluorouracil; Gatifloxacin; Hand-Foot Syndrome; Humans; Lacrimal Duct Obstruction | 2015 |
[The present status of CapeOX as adjuvant chemotherapy for colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies | 2015 |
Images in clinical medicine. Loss of fingerprints.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermatoglyphics; Female; Fingers; Fluorouracil; Hand-Foot Syndrome; Humans | 2015 |
Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Risk Factors | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Diarrhea; Disease Progression; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Retrospective Studies; Survival Rate; Triazoles | 2015 |
Unilateral Capecitabine-related Hand-foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Risk Factors; Syndrome | 2015 |
Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Female; Hand-Foot Syndrome; Humans; Middle Aged | 2015 |
Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Management; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Education as Topic; Quality of Life; Self Care; Young Adult | 2016 |
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2016 |
[Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Cisplatin; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Leukopenia; Neutropenia; Prospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Female; Follow-Up Studies; Hand-Foot Syndrome; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Odds Ratio; Proportional Hazards Models; Risk Factors | 2017 |
Capecitabine and the Risk of Fingerprint Loss.
Topics: Capecitabine; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dermatoglyphics; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Skin Diseases, Genetic | 2017 |
The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Capecitabine; Cell Line; Cell Proliferation; Disease Models, Animal; Hand-Foot Syndrome; Humans; Keratinocytes; Male; Membrane Potential, Mitochondrial; Mice, Inbred ICR | 2017 |
Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Drug Eruptions; Genital Diseases, Male; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Metastasis; Penile Diseases; Scrotum; Skin Ulcer | 2017 |
Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Denmark; Drug Combinations; Drug Substitution; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Netherlands; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Outcome; Western World | 2017 |
Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data.
Topics: Antineoplastic Agents; Bayes Theorem; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Empirical Research; Fluorouracil; Hand-Foot Syndrome; Humans; Markov Chains | 2011 |
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
Topics: Adaptation, Physiological; Algorithms; Antimetabolites, Antineoplastic; Bayes Theorem; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Hand-Foot Syndrome; Humans; Markov Chains; Metabolic Clearance Rate; Models, Biological; Prodrugs; Prognosis; Treatment Outcome | 2012 |
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Topics: Adverse Drug Reaction Reporting Systems; Capecitabine; Data Mining; Deoxycytidine; Diarrhea; Fluorouracil; Hand-Foot Syndrome; Humans; Leukopenia; Nausea; Neutropenia; Reproducibility of Results; Thrombocytopenia; United States; United States Food and Drug Administration; Vomiting | 2012 |
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Prospective Studies | 2013 |
Chemotherapy and fingerprint loss: beyond cosmetic.
Topics: Capecitabine; Deoxycytidine; Dermatoglyphics; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Quality of Life | 2012 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Leukopenia; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Remission Induction; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Hyperpigmentation; Male; Remission, Spontaneous | 2012 |
[Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging | 2012 |
Hand-foot syndrome related to chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2012 |
Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia.
Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lupus Erythematosus, Systemic; Middle Aged; Prodrugs | 2012 |
Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Middle Aged; Prodrugs; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2012 |
Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.
Topics: 2-Propanol; Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Camphor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dermatologic Agents; Drug Combinations; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Plant Extracts; Treatment Outcome | 2010 |
[Breast cancer and the hand-foot syndrome].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paris; Prospective Studies; Risk Factors | 2012 |
[Therapy traces on hands and feet in a patient with colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Palliative Care | 2012 |
Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Hypertriglyceridemia; Pancreatitis, Acute Necrotizing; Triglycerides | 2012 |
[Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Outpatients; Quality of Life | 2012 |